All Posts
  • Press Releases
1 min read

Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

On this page

Share

On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026

TRX319 is an allogeneic CAR-Tr1 Treg cell therapy designed to pair targeted B-cell control with active anti-inflammatory signaling and pathogenic T-cell modulation in a CNS-penetrant package

Related Articles

Explore posts connected to this topic

View Resources

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

...
  • Videos

Scaling Smarter: a Case Study in Overcoming Cell Therapy Manufacturing & Regulatory Hurdles

Cell & Gene Therapy Insights Webinar titled "Scaling Smarter: a
  • Videos

Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) — Tr1X, Inc.

  • Press Releases

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing

  • Videos
Cell & Gene Therapy Insights Webinar titled "Scaling Smarter: a
  • Videos

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) — Tr1X, Inc.

  • Press Releases